



28 August 2019

Australian Securities Exchange
20 Bridge Street,
Sydney NSW 2000

Change of Director's Interest Notice

Melbourne, Victoria – Alcidion Group Limited (ASX:ALC) (**Company**) attaches an Appendix 3Y for Mr Raymond Blight in relation to a recent on-market disposal of fully paid ordinary shares by his spouse (Indirect Interest). The Company notes that the shares were traded during a Closed period under its Securities Trading Policy. The Closed period relates to the forthcoming release of the Company's full year results.

Alcidion's Continuous Disclosure Policy, available on the Company's website, requires Directors to notify the Company Secretary if they consider there is material information which requires disclosure and are encouraged to approach the Company Secretary if they have any queries about what information should be disclosed to the market. Further, Alcidion's Securities Trading Policy requires that a Director must request clearance to trade in the Company's securities in all circumstances and notify the Company Secretary of any trading conducted in accordance with the Policy within 2 business days of such trades occurring. Alcidion provides a pack to all new directors at the commencement of their tenure containing, amongst other documents, the Continuous Disclosure Policy and Securities Trading Policy. These arrangements are being reinforced and clarified with all Directors.

The circumstances surrounding the breach of the Company's Securities Trading Policy in respect of the sale of shares by Mr Blight's spouse are that Mr Blight was unaware of the sale at the time the shares were sold as his spouse independently manages her financial affairs, and Mr Blight was not privy to that information.

This notice was prepared and lodged as soon as practicable once the Company became aware of the trading details.

The Company takes very seriously any breaches of the Alcidion Securities Trading Policy. The Company has discussed this with Mr Blight and notes that he is aware of the Closed periods and processes required to be complied with under the Company's Securities Trading Policy. The Company is confident that the arrangements and training/education measures it currently has in place to ensure Directors are aware of the requirements under the Company's Securities Trading Policy are adequate.

ENDS

For further information, please contact:

Kyahn Williamson,
WE Buchan
Ph: 0401018828
kwilliamson@we-buchan.com



About Alcidion

Alcidion Limited (ASX:ALC) has a simple purpose: to transform healthcare with smart, intuitive technology solutions that meet the needs of hospital and allied healthcare, worldwide. It offers a complementary set of software products and services that create a unique offering in the global healthcare market; solutions that support interoperability, allow communication and task management, and deliver clinical decision support at the point of care to improve patient outcomes. In 2017 Alcidion acquired Oncall System and its Smartpage clinical communication system. In 2018 it acquired the Patientrack bedside patient monitoring software and MKM Health, an IT solutions and services provider. These offerings now operate under the Alcidion brand. With over 25 years of combined healthcare experience, Alcidion brings together the very best in technology and market knowledge to deliver solutions that make healthcare better for everyone.

www.alcidion.com

© Alcidion Group Limited 2019. Alcidion, MKM Health, Miya, Patientrack and Smartpage are registered trademarks. All other brands and product names and trademarks are the registered property of their respective companies.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ALCIDION GROUP LIMITED
ABN	77 143 142 410

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Raymond Howard Blight
Date of last notice	4 April 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Ms Robyn Gaile Morris (Spouse of Mr Raymond Blight)
Date of change	22 August 2019
No. of securities held prior to change	Direct 96,028,781 Fully Paid Ordinary Shares Indirect 5,235,340 Fully Paid Ordinary Shares
Class	Fully Paid Ordinary Shares
Number acquired	Nil
Number disposed	686,040
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$88,499.81

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

No. of securities held after change	Direct 96,028,781 Fully Paid Ordinary Shares Indirect 4,549,300 Fully Paid Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market Trade

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.